Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial - Wikidata - awgldk - TriplyDB

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial

http://www.wikidata.org/entity/Q33604322

about

Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis.Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.Switching antiretroviral regimes for the treatment of HIV: safety implications.Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

P2860

Q36220644-5DCA2D8C-B9D1-414F-BDB3-48F3A0BF6DEF Q36303488-FC3E44F2-D91E-4AD8-81FD-3F6B07B4C847 Q36343650-7BF265BB-668B-485D-8300-2AE9D287A88D Q36426953-326A147F-21BF-4DC3-AE7F-5AD35BBFB6B0 Q37279429-0EE13A59-F352-4C21-A789-12FAB11EB602 Q37328870-8A3C098E-5778-4F13-A242-AC364A45EDD9 Q38879406-4998D4E9-C68B-4F58-A167-3F7B1D4B9F5D Q39426047-362A0A8C-A579-4714-BF42-7D671817180D Q57180790-0B6453FD-F419-49B0-AB06-E089E2A83A8E

P2860

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial

http://www.wikidata.org/entity/Q33604322

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Simplification to abacavir/lam ...... n label, non-inferiority trial

@ast

Simplification to abacavir/lam ...... n label, non-inferiority trial

@en

type

label

Simplification to abacavir/lam ...... n label, non-inferiority trial

@ast

Simplification to abacavir/lam ...... n label, non-inferiority trial

@en

prefLabel

Simplification to abacavir/lam ...... n label, non-inferiority trial

@ast

Simplification to abacavir/lam ...... n label, non-inferiority trial

@en

P1433

Q33604322-18914706-69C4-4B12-9A58-650AFB6ED253

P1476

Q33604322-E573C43C-8315-4674-A2A0-953627A76435

P2093

Q33604322-1F790131-7D4C-46DD-A386-91C45675AC7F

Q33604322-39B4E660-A08F-45CC-A3C4-78AAB9865348

Q33604322-5E9B9336-A1CF-49EF-9720-4AFDA1D25100

Q33604322-5FC9ECE3-0FFC-4D53-A032-42542B179A18

Q33604322-72C42055-FACA-4AEE-9072-2213E8A6CAA3

Q33604322-C9434E54-8523-461E-B48C-FCB4D8FCC9FD

Q33604322-CA1BC49B-9375-45E9-BEA2-144F3266887E

Q33604322-CB771B4D-63A2-4AF9-8A78-80BCC6761A5D

Q33604322-F3CEE06D-1FCF-477E-8A6C-B5CA2F8F0AAE

P2860

Q33604322-0B7350D9-6B02-4607-90CD-41C4B227564B

Q33604322-0F19A044-0AB8-4255-B9C7-07FFEAD9DBF5

Q33604322-1EF90268-56CA-4588-BB6A-36357326EB92

Q33604322-27FBBADD-61AF-454B-9C63-4839A7013FE2

Q33604322-28F40748-F684-441F-A30F-E911A5B9889F

Q33604322-325A31AD-3E63-4409-8747-46771149DC7F

Q33604322-38607121-F539-417B-909C-8081F7667C9F

Q33604322-3CD55AC7-EC0C-4FA6-BF53-7D3AE5063663

Q33604322-3D4A1A12-EAC5-4CF5-9717-9437CEE833E3

Q33604322-3EF17C69-DE23-4755-A0C7-49E68A81F10B

P304

Q33604322-020603DC-17E4-4825-A9E3-970EC1B9FAED

P31

Q33604322-0A350D7C-433A-4C6E-BE6B-D57BF72AE70E

P356

Q33604322-6E874B0F-212B-47E3-B829-E8ACDBCB34C3

P407

Q33604322-F5C12D00-6B95-4210-A6B7-01C054E8477E

P433

Q33604322-F595B5ED-4295-4278-8F61-62EC7F38899F

P478

Q33604322-E8EE6917-928C-4130-BFE1-55D5F08E1C94

P50

Q33604322-D71B79D2-3A7F-4CBC-A54B-B5D9085ACAEB

P577

Q33604322-5A045005-1C86-4B98-9056-B646826BF1F4

P5875

Q33604322-72EE9620-5D37-4707-A2EB-5D74525B1EB5

P698

Q33604322-9C1AAC7A-D298-4EEA-AD93-1B7EBA647882

P921

Q33604322-65567497-4B0A-4A0F-BB9C-1ECDA3A1114D

P932

Q33604322-5517EF96-F234-4223-8B34-61D2784AE05B

P356

JOURNAL.PONE.0096187

P1433

P1476

Simplification to abacavir/lam ...... n label, non-inferiority trial

@en

P2093

Catherine B Small

http://www.w3.org/2001/XMLSchema#string

David A Margolis

http://www.w3.org/2001/XMLSchema#string

David A Wohl

http://www.w3.org/2001/XMLSchema#string

Edwin DeJesus

http://www.w3.org/2001/XMLSchema#string

Henry H Zhao

http://www.w3.org/2001/XMLSchema#string

Howard Edelstein

http://www.w3.org/2001/XMLSchema#string

Laveeza Bhatti

http://www.w3.org/2001/XMLSchema#string

Lisa L Ross

http://www.w3.org/2001/XMLSchema#string

Winkler G Weinberg

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine

Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir.

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

P304

e96187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0096187

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262307372

http://www.w3.org/2001/XMLSchema#string

P698

24825167

http://www.w3.org/2001/XMLSchema#string

P921

P932

4019479

http://www.w3.org/2001/XMLSchema#string